Promise Against Melanoma With Immunotherapy

Researchers have unleashed the immune system to attack skin cancer and have made important strides against melanoma, reveal the results of three clinical trials released Monday. The first study presented at the American Society of Clinical Oncology annual meeting showed patients given a drug called Yervoy (ipilimumab), made by Bristol Myers-Squibb, saw a 25 percent reduced risk of the cancer coming back when compared to a placebo. The study involved ...